title: Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013.
abstract: In 1988, the World Health Assembly resolved to eradicate poliomyelitis worldwide. One of the main tools used in polio eradication efforts has been live, attenuated oral poliovirus vaccine (OPV), an inexpensive vaccine easily administered by trained volunteers. OPV might require several doses to induce immunity, but then it provides long-term protection against paralytic disease through durable humoral immunity. Rare cases of vaccine-associated paralytic poliomyelitis can occur among immunologically normal OPV recipients, their contacts, and persons who are immunodeficient. In addition, vaccine-derived polioviruses (VDPVs) can emerge in areas with low OPV coverage to cause polio outbreaks and can replicate for years in persons who have primary, B-cell immunodeficiencies. This report updates previous surveillance summaries and describes VDPVs detected worldwide during July 2012-December 2013. Those include a new circulating VDPV (cVDPV) outbreak identified in Pakistan in 2012, with spread to Afghanistan; an outbreak in Afghanistan previously identified in 2009 that continued into 2013; a new outbreak in Chad that spread to Cameroon, Niger, and northeastern Nigeria; and an outbreak that began in Somalia in 2008 that continued and spread to Kenya in 2013. A large outbreak in Nigeria that was identified in 2005 was nearly stopped by the end of 2013. Additionally, 10 newly identified persons in eight countries were found to excrete immunodeficiency-associated VDPVs (iVDPVs), and VDPVs were found among immunocompetent persons and environmental samples in 13 countries. Because the majority of VDPV isolates are type 2, the World Health Organization has developed a plan for coordinated worldwide replacement of trivalent OPV (tOPV) with bivalent OPV (bOPV; types 1 and 3) by 2016, preceded by introduction of at least 1 dose of inactivated poliovirus vaccine (IPV) containing all three poliovirus serotypes into routine immunization schedules worldwide to ensure high population immunity to all polioviruses.
authors.forename: Ousmane M
authors.initials: OM
authors.lastname: Diop
authors.forename: Cara C
authors.initials: CC
authors.lastname: Burns
authors.forename: Steven G
authors.initials: SG
authors.lastname: Wassilak
authors.forename: Olen M
authors.initials: OM
authors.lastname: Kew
mesh_terms: D002675:Child, Preschool; D005260:Female; D014943:Global Health / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D008297:Male; D011051:Poliomyelitis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D017955:Poliovirus / Q000145:classification / Q000302:isolation & purification*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects*; D012703:Serotyping; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011055:Poliovirus Vaccine, Oral; D014613:Vaccines, Attenuated